From new trial data to cost comparisons with surgery, a wave of new findings is adding to the framework of how GLP-1s are being used and tested.  Here are four recent GLP-1 developments: 

Eli Lilly said its experimental oral GLP-1 drug orforglipron outperformed Novo Nordisk’s oral semaglutide in a 52-week phase 3 study analyzing 1,698 adults with Type 2 diabetes. The highest dose of orforglipron lowered average blood sugar by 2.2%, compared to 1.4% for semaglutide and patients lost an average of 9.2% of their weight versus 5.3% with Novo Nordisk’s pill.

Eli Lilly  also said its injectable GLP-1 Mounjaro helped children ages 10-17 with Type 2 diabetes reduce blood sugar levels by an average of 2% and lose more than 10% of their weight in a yearlong study, Bloomberg reported Sept. 17. E

See Full Page